Ingrid Glimelius

Ingrid Glimelius

Auto-generated profile, based on publicly available information

Ingrid Glimelius

Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2003 in JAMA
Verified
Journal Article
Open access
PDF file
LTLois B. Travis
Lois B. Travis
DHDeirdre A. Hill
Deirdre A. Hill
GDGraça M. Dores
Graça M. Dores
MGMary Gospodarowicz
Mary Gospodarowicz
FLFlora E. van Leeuwen
Flora E. van Leeuwen
EGEthel Gilbert
Ethel Gilbert
Treatment of Hodgkin disease (HD) represents one of the major medical successes of the 20th century. Fifty years ago, the typical patient survived only a few years,1 whereas the current 5-year relative survival rate is 85%.2 In the United States alone, approximately 120 000 survivors of HD2 are at risk for the serious late sequelae of curative therapies, including the occurrence of new primary cancers.3,4 Second malignant neoplasms are now the leading cause of death in long-term survivors of HD,5,6 with breast cancer representing the most frequent solid tumor among women.

24 February 2018 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
RTRebecca Troisi
Rebecca Troisi
TBT. Bjørge
T. Bjørge
MGM. Gissler
M. Gissler
TGT. Grotmol
T. Grotmol
CKC. M. Kitahara
C. M. Kitahara
IGI. Glimelius
I. Glimelius
An understanding of the origin of cancer is critical for cancer prevention and treatment. Complex biological mechanisms promote carcinogenesis, and there is increasing evidence that pregnancy‐related exposures influence foetal growth cell division and organ functioning and may have a long‐lasting impact on health and disease susceptibility in the mothers and offspring. Nulliparity is an established risk factor for breast, ovarian, endometrial and possibly pancreatic cancer, whilst the risk of kidney cancer is elevated in parous compared with nulliparous women. For breast, endometrial and ovarian cancer, each pregnancy provides an additional risk reduction. The associations of parity with thyroid and colorectal cancers are uncertain. The timing of reproductive events is also recognized to be important. Older age at first birth is associated with an increased risk of breast cancer, and older age at last birth is associated with a reduced risk of endometrial cancer. The risks of breast and endometrial cancers increase with younger age at menarche and older age at menopause. The mechanisms, and hormone profiles, that underlie alterations in maternal cancer risk are not fully understood and may differ by malignancy. Linking health registries and pooling of data in the Nordic countries have provided opportunities to conduct epidemiologic research of pregnancy exposures and subsequent cancer. We review the maternal risk of several malignancies, including those with a well‐known hormonal aetiology and those with less established relationships. The tendency for women to have fewer pregnancies and at later ages, together with the age‐dependent increase in the incidence of most malignancies, is expected to affect the incidence of pregnancy‐associated cancer.

5 November 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MMMohammad Mohammadi
Mohammad Mohammadi
YCYang CAO
Yang CAO
IGIngrid Glimelius
Ingrid Glimelius
MBMatteo Bottai
Matteo Bottai
SESandra Eloranta
Sandra Eloranta
KSKarin Ekström Smedby
Karin Ekström Smedby
Comorbidity increases overall mortality in patients diagnosed with hematological malignancies. The impact of comorbidity on cancer-specific mortality, taking competing risks into account, has not been evaluated. Using the Swedish Cancer Register, we identified patients aged >18 years with a first diagnosis of acute myeloid leukemia (AML, N = 2,550), chronic myeloid leukemia (CML, N = 1,000) or myeloma (N = 4,584) 2002–2009. Comorbid disease history was assessed through in- and out-patient care as defined in the Charlson comorbidity index. Mortality rate ratios (MRR) were estimated through 2012 using Poisson regression. Probabilities of cancer-specific death were computed using flexible parametric survival models. Comorbidity was associated with increased all-cause as well as cancer-specific mortality (cancer-specific MRR: AML = 1.27, 95 % CI: 1.15–1.40; CML = 1.28, 0.96–1.70; myeloma = 1.17, 1.08–1.28) compared with patients without comorbidity. Disorders associated with higher cancer-specific mortality were renal disease (in patients with AML, CML and myeloma), cerebrovascular conditions, dementia, psychiatric disease (AML, myeloma), liver and rheumatic disease (AML), cardiovascular and pulmonary disease (myeloma). The difference in the probability of cancer-specific death, comparing patients with and without comorbidity, was largest among AML patients <70 years, whereas in myeloma the difference did not vary by age among the elderly. The probability of cancer-specific death was generally higher than other-cause death even in older age groups, irrespective of comorbidity. Comorbidities associated with organ failure or cognitive function are associated with poorer prognosis in several hematological malignancies, likely due to lower treatment tolerability. The results highlight the need for a better balance between treatment toxicity and efficacy in comorbid and elderly AML, CML and myeloma patients.

4 August 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JRJoana M. Rodrigues
Joana M. Rodrigues
MHMay Hassan
May Hassan
CFCatja Freiburghaus
Catja Freiburghaus
CEChristian W. Eskelund
Christian W. Eskelund
CGChristian Geisler
Christian Geisler
SESara Ek
Sara Ek
Summary: Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy‐based treatments and have poor prognosis. Thus, there is a clinical need to identify missense mutations through routine analysis to enable patient stratification. Sequencing is not widely implemented in clinical practice for MCL, and immunohistochemistry (IHC) is a feasible alternative to identify high‐risk patients. The aim of the present study was to investigate the accuracy of p53 as a tool to identify patients withTP53missense mutations and the prognostic impact of overexpression and mutations in a Swedish population‐based cohort. In total, 317 cases were investigated using IHC and 255 cases were sequenced, enabling analysis of p53 andTP53status among 137 cases divided over the two‐cohort investigated. The accuracy of predicting missense mutations from protein expression was 82%, with sensitivity at 82% and specificity at 100% in paired samples. We further show the impact of p53 expression andTP53mutations on survival (hazard ratio of 3·1 in univariate analysis for both), and the association to risk factors, such as high MCL International Prognostic Index, blastoid morphology and proliferation, in a population‐based setting.

6 October 2015 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
IGIngrid Glimelius
Ingrid Glimelius
SESara Ekberg
Sara Ekberg
MJMats Jerkeman
Mats Jerkeman
ECEllen T. Chang
Ellen T. Chang
MBMagnus Björkholm
Magnus Björkholm
SESandra Eloranta
Sandra Eloranta

8 August 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
PHPeter Hollander
Peter Hollander
PKPeter Kamper
Peter Kamper
KSKarin Ekstrom Smedby
Karin Ekstrom Smedby
GEGunilla Enblad
Gunilla Enblad
MLMaja Ludvigsen
Maja Ludvigsen
IGIngrid Glimelius
Ingrid Glimelius
Key Points: High proportions of PD-1+ and PD-L1+ leukocytes in the Hodgkin lymphoma microenvironment are associated with inferior outcome. Expression of PD-L1 and PD-L2 on Hodgkin and Reed-Sternberg cells has no impact on outcome.